Overview

A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

Status:
Active, not recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This Phase 2 study is conducted to assess the efficacy and safety of DS-1001b in patients with chemotherapy- and radiotherapy-naive IDH1 mutated WHO grade II glioma.
Phase:
Phase 2
Details
Lead Sponsor:
Daiichi Sankyo Co., Ltd.